Genentech, a member of the Roche Group, is set to present new data from its Alzheimer’s disease portfolio at the Alzheimer’s Association International Conference® 2026 in London on July 12-15. These findings showcase the companies’ ongoing commitment to developing next-generation treatments and diagnostic tests aimed at slowing or stopping the progression of Alzheimer’s disease.

A growing tide of clinical research is transforming synovial sarcoma treatment prospects. According to DelveInsight Business Research LLP, over 15 pharmaceutical firms are developing more than 20 new therapies, reflecting a heightened commitment to tackling this rare cancer.